Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $454.57M
• Dividend Yield: N/A
• Average Volume (3M): 1.39M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -17.37%
• EPS Growth: 52.28%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 381,995,120
• 10 Day Avg. Volume: 1,634,197
• 30 Day Avg. Volume: 1,385,775
• PEG Ratio: 0.10
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 3.54
• P/FCF Ratio: -4.07
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 4.02
• Enterprise Value/Ebitda: -2.65
• 1Y Price Target: $1.35
• Price Target Upside: 19.47% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.00 ▼(-11.50% Downside)

The overall stock score is primarily impacted by the company's poor financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. These factors collectively indicate significant challenges for the company, requiring strategic improvements to enhance performance.

Positive Factors

Low Debt Levels

Low debt levels provide financial flexibility and reduce risk, allowing the company to invest in growth opportunities without significant financial strain.

Stable Gross Profit Margin

A stable gross profit margin indicates efficient cost management and pricing power, which can support profitability as revenues recover.

Strategic Partnerships

Strategic partnerships can drive innovation and expand market reach, enhancing long-term revenue potential through collaborative research and product development.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market demand or competitive positioning, which can impact long-term growth and profitability.

Negative Cash Flow

Negative cash flow limits the company's ability to fund operations and growth initiatives, potentially leading to liquidity issues if not addressed.

Persistent Losses

Ongoing losses reflect operational inefficiencies and market challenges, which can erode shareholder value and hinder strategic investments.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue through multiple key streams, primarily by selling its proprietary laboratory instruments, consumables, and software solutions to research institutions, pharmaceutical companies, and clinical laboratories. The company also benefits from ongoing service contracts and maintenance agreements for its equipment, which provide a steady revenue flow. Additionally, Standard BioTools engages in strategic partnerships with academic institutions and industry players, allowing for collaborative research efforts that can lead to innovative product development and expanded market reach. These partnerships often include licensing agreements, which can further enhance the company's revenue potential.

Standard BioTools Financial Statement Overview

Summary

Standard BioTools is facing significant financial challenges with declining revenues and persistent losses. Despite a low debt level, the negative profitability and cash flow issues are major concerns, indicating a need for strategic improvements.

Income Statement

Standard BioTools has faced declining revenue with a negative growth rate of -16.48% in the TTM. The company is struggling with profitability, as indicated by negative net profit and EBIT margins. Gross profit margin remains relatively stable at 47.94%, but the overall financial performance is hindered by significant losses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.069, indicating low leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a relatively strong equity position compared to its total assets.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, suggesting cash flow challenges. The free cash flow to net income ratio is above 1, indicating that free cash flow exceeds net income, but both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	128.83M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	61.76M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-93.61M	-118.14M	-54.46M	-173.57M	-44.27M	-34.60M
Net Income	-128.25M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	539.64M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	194.90M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	27.39M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	139.98M	140.62M	471.12M	471.78M	180.62M	185.71M
Stockholders Equity	399.66M	471.72M	-148.05M	-81.47M	94.60M	139.05M
Cash Flow
Free Cash Flow	-98.42M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-87.21M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	61.17M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-54.57M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.30, and below the 200-day MA of 1.24, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.56 is Neutral, neither overbought nor oversold. The STOCH value of 15.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	64 Neutral	$772.00M	13.10	24.11%	―	14.46%	―
CSTL	62 Neutral	$979.28M	―	-2.69%	―	10.15%	-295.52%
FLGT	60 Neutral	$697.27M	―	-4.54%	―	4.31%	69.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	51 Neutral	$613.35M	―	-72.52%	―	0.21%	-233.51%
PSNL	43 Neutral	$680.24M	―	-43.69%	―	-21.02%	47.74%
LAB	41 Neutral	$454.57M	-3.72	-24.63%	―	-17.37%	52.28%

Standard BioTools Corporate Events

Standard BioTools Inc. Reports Q3 2025 Financial Results

Standard BioTools Inc., a prominent player in the biomedical research sector, specializes in providing next-generation technologies such as SomaScan, mass cytometry, and microfluidics to aid researchers in developing better medicines. The company recently reported its financial results for the third quarter of 2025, highlighting a total combined revenue of $46.2 million, with $19.6 million from continuing operations. The company is undergoing a significant restructuring plan aimed at achieving over $40 million in annualized cost savings, setting a path towards positive adjusted EBITDA by 2026.

Standard BioTools Implements Restructuring for Future Growth

Standard BioTools reported a third-quarter 2025 revenue of $19.6 million from continuing operations, marking an 11% decline year-over-year. The company has implemented a restructuring plan expected to save $40 million annually, with a goal of achieving positive adjusted EBITDA by 2026. The restructuring includes a 20% workforce reduction and consolidating operations to improve efficiency. The company anticipates a significant cash boost from a pending transaction with Illumina, which will support its growth strategy through mergers and acquisitions.

The most recent analyst rating on (LAB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Announces Workforce Reduction Plan

On September 13, 2025, Standard BioTools Inc. initiated a restructuring plan, which includes a 15% reduction in its global workforce. This move aims to enhance operational efficiency and align costs with revenue projections, supporting the company’s long-term strategic goals. The restructuring is expected to incur expenses of approximately $7.5 million, primarily for severance and termination benefits, with potential for additional unforeseen costs.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Announces Strategic Restructuring Plan

On August 28, 2025, Standard BioTools Inc. announced a strategic restructuring plan to consolidate its R&D capabilities from South San Francisco to its Singapore facility, aligning with its manufacturing operations. This move, aimed at enhancing operational efficiency and reducing costs, involves a reduction-in-force affecting U.S. employees and is expected to incur expenses of approximately $3.6 million, with potential for additional costs due to unforeseen events.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard Biotools Inc. Faces Challenges in SomaScan Divestiture: Potential Risks and Strategic Imperatives

Standard Biotools Inc. faces significant risks in realizing the anticipated benefits from its recent Transaction, particularly if it fails to divest the SomaScan Business. The company may encounter material adverse effects such as management distraction, employee loss, and challenges in managing the divestiture, which could hinder cost savings and impact financial performance. These issues, largely beyond the company’s control, could lead to increased costs, reduced revenues, and a potential decline in stock market value, thereby affecting its overall business prospects. Such risks underscore the importance of effective management and strategic planning to mitigate potential negative outcomes.

Standard BioTools Delays Quarterly Report Filing

Standard BioTools Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the time required to complete financial closing procedures and finalize adjustments necessary to reflect the disposal group as discontinued operations. This is related to a stock purchase agreement entered into on June 22, 2025, for the sale of its subsidiaries, SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd. The company expects to file the report within the five-day extension period allowed under Rule 12b-25. There is an anticipation of significant changes in financial results from the previous year, although specific details are not provided. Forward-looking statements are included, indicating potential risks and uncertainties. Standard BioTools is actively working on compliance and the notification is signed by Alex Kim, the Chief Financial Officer.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Reports Q2 2025 Financial Results

Standard BioTools Inc., a prominent player in the biomedical research sector, specializes in providing advanced technologies for scientific discoveries, focusing on areas such as oncology and immunotherapy. The company reported its financial results for the second quarter of 2025, highlighting a strategic sale and financial performance.

Standard BioTools Announces SomaLogic Sale to Illumina

Standard BioTools reported its financial results for the second quarter of 2025, highlighting a total revenue of $42 million, with $21.8 million from continuing operations. The company announced the strategic sale of SomaLogic to Illumina for up to $425 million, expected to close in the first half of 2026, which will significantly bolster its cash reserves to at least $550 million. This move is part of a broader strategy to streamline operations and focus on profitability by 2026, despite challenges such as reduced U.S. academic spending and global capital constraints. The company is pausing its earnings calls temporarily to focus on operational adjustments.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.